Cantargia Reports Organisational Change
Tweet
Share
E-mailLUND, SWEDEN / ACCESSWIRE / July 22, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today announced that its Chief Operating Officer (COO), Liselotte Larsson has resigned and will continue her career outside Cantargia. She will depart her role by mid-October, 2024.
"Liselotte joined Cantargia before our public listing and has played an important role to advance Cantargia's two projects into clinical stage, for which I feel great gratitude. On behalf of the entire company, I want to wish Liselotte the best of luck in future new opportunities," says Göran Forsberg, CEO of Cantargia.
Liselotte Larsson joined Cantargia in 2014 and during her time at the company, she has played an important role in building the company. The process to recruit a replacement has begun.
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: [email protected]
About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive interim data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.
Attachments
Cantargia reports organisational change
SOURCE: Cantargia
View the original press release on accesswire.com
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: Iran cannot have, in any way, shape, or form, a nuclear weapon
- Praxis Precision Medicines Inc. (PRAX) PT Raised to $945 at Raymond James
- Morgan Stanley sees AI financing as defining summer 2026
Create E-mail Alert Related Categories
ACCESS Newswire, Press ReleasesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
